Cancer treatment receives EU drug designations
Cell Medica, who develop, market and manufacture cellular therapeutics for cancer and viral infections, has received European Commission orphan drug designations for CMD-003 (baltaleucel-T) as a cancer treatment for extranodal NK/T-cell lymphoma, nasal type, and post-transplant lymphoproliferative disorder.
Click on this link for more information.
